Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Fancy who wrote (4472)	6/12/1998 2:28:00 AM
From: scaram(o)uche	Respond to of 6136

Apparently there was "huffing, puffing, blow the house down" at the the IMNR annual meeting. This post is from Yahoo...... Items BuySDBio (M/San Diego) Jun 12 1998 1:41AM EDT The following questions were asked after Dr. Carlo's presentation. (Not verbatim.) Since the DSMB extended the Phase III Remune trials is there any chance of receiving an early approval? Dr. Carlo answered, In the early 1990's alot of people thought immune based therapies were going to be the cure for Aids. At that time there was very little concrete data to back -up that opinion and consequently the attention was turned to anti-viral drugs. When the wave of hope turned to the anti-virals they were quickly brought to market. With the data we have now which will be presented at the Geneva conference the attention could move back to immune based therapies. (snip) Between this and the Johnson's statement today in the release, you'd think that somebody at IMNR will be able to WALK to Geneva.... without sinking. :-) Can't wait! Rick

To: Steve Fancy who wrote (4472)	6/12/1998 7:18:00 AM
From: sam	Read Replies (1) \| Respond to of 6136

From the Wall Street Journal (p. B6): "Remune could help Agouron build 'critical mass,' in the AIDS market, said Tony Butler, an analyst at Lehman Brothers Inc. There is also the possibility that a Remune drug cocktail might encourage HIV-infected patients to begin drug therapy sooner. That, in turn, could boost sales of Viracept and other antiviral drugs."

To: Steve Fancy who wrote (4472)	6/12/1998 12:13:00 PM
From: Steve Fancy	Respond to of 6136

RESEARCH ALERT - Agouron (NASDAQ:AGPH) raised to buy Reuters, Friday, June 12, 1998 at 12:06 NEW YORK, June 12 (Reuters) - BT Alex. Brown analysts Kevin Tang and Patrick Cheng raised their rating for Agouron Pharmaceuticals Inc. Friday to buy from market perform. -- In a report, they said a deal between Agouron and Immune Response Corp. (NASDAQ:IMNR) would help Agouron. The agreement calls for collaboration on developing and commercializing Remune, Immune Response's drug for HIV infection. -- "We believe that Agouron negotiated a deal that represents a good risk/reward profile for its shareholders." -- They set a new 12-month price target of $48 for the stock. Agouron was up 3/16 to 33-15/16 and Immune Response fell 8/16 to 13-3/16. Copyright 1998, Reuters News Service Companies o